Aegis Life, Inc.
Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat infectious diseases by developing nucleic acid-based vaccines and therapeutics utilizing the Fusogenix Proteolipid Vehicle (PLV) delivery platform. The company leverages its proprietary Fusogenix platform to accelerate discovery, clinical development, and manufacturing of vaccines and therapeutics for infectious diseases, aiming to provide rapid deployment and scalable production of DNA vaccines and therapies.
Industries
Nr. of Employees
small (1-50)
Products
SARS-CoV-2 DNA vaccine candidate (spike protein encoded)
A plasmid DNA vaccine candidate formulated in a proteolipid vehicle to deliver genetic instructions encoding the SARS-CoV-2 spike protein for intramuscular administration; developed for single-dose or booster regimens and early-phase clinical evaluation.
Pan-coronavirus DNA vaccine candidate (multi-antigen)
A plasmid DNA vaccine approach designed to express multiple conserved coronavirus antigens (e.g., spike, nucleocapsid, membrane) formulated in a proteolipid vehicle to broaden variant coverage and durability.
DNA-encoded monoclonal antibody therapeutic programs
Programmatic development of plasmid DNA constructs intended to direct in vivo expression of neutralizing monoclonal antibodies for infectious diseases (example targets include HIV and malaria), delivered via a proteolipid vehicle for intramuscular administration.
SARS-CoV-2 DNA vaccine candidate (spike protein encoded)
A plasmid DNA vaccine candidate formulated in a proteolipid vehicle to deliver genetic instructions encoding the SARS-CoV-2 spike protein for intramuscular administration; developed for single-dose or booster regimens and early-phase clinical evaluation.
Pan-coronavirus DNA vaccine candidate (multi-antigen)
A plasmid DNA vaccine approach designed to express multiple conserved coronavirus antigens (e.g., spike, nucleocapsid, membrane) formulated in a proteolipid vehicle to broaden variant coverage and durability.
DNA-encoded monoclonal antibody therapeutic programs
Programmatic development of plasmid DNA constructs intended to direct in vivo expression of neutralizing monoclonal antibodies for infectious diseases (example targets include HIV and malaria), delivered via a proteolipid vehicle for intramuscular administration.
Services
Preclinical development and in vivo efficacy/toxicity studies
Design and conduct of animal model studies evaluating immunogenicity, efficacy, and safety of nucleic acid vaccine and therapeutic candidates.
GMP manufacturing scale-up and technology transfer for nanoparticle formulations
Implementation and transfer of microfluidic GMP manufacturing systems and processes for clinical-grade production of nucleic acid‑loaded proteolipid vehicles, including partnerships for equipment deployment and process support.
Downstream process development for delivery platform components
Process development for purification and manufacturing of protein components used in delivery formulations to meet GMP quality attributes.
Clinical trial support and early-phase study management
Operational support and partnership for Phase 1/2 clinical trials including site partnerships, protocol advancement, dosing, and immunogenicity/safety assessments.
Vector and plasmid optimization services
Optimization and licensing-based use of small, high-expression plasmid vectors designed for improved expression, manufacturability, and selection marker alternatives suitable for clinical manufacturing.
Preclinical development and in vivo efficacy/toxicity studies
Design and conduct of animal model studies evaluating immunogenicity, efficacy, and safety of nucleic acid vaccine and therapeutic candidates.
GMP manufacturing scale-up and technology transfer for nanoparticle formulations
Implementation and transfer of microfluidic GMP manufacturing systems and processes for clinical-grade production of nucleic acid‑loaded proteolipid vehicles, including partnerships for equipment deployment and process support.
Downstream process development for delivery platform components
Process development for purification and manufacturing of protein components used in delivery formulations to meet GMP quality attributes.
Clinical trial support and early-phase study management
Operational support and partnership for Phase 1/2 clinical trials including site partnerships, protocol advancement, dosing, and immunogenicity/safety assessments.
Vector and plasmid optimization services
Optimization and licensing-based use of small, high-expression plasmid vectors designed for improved expression, manufacturability, and selection marker alternatives suitable for clinical manufacturing.
Expertise Areas
- Nucleic acid vaccine development
- Nucleic acid therapeutic development (DNA and RNA modalities)
- Intracellular delivery platform engineering
- Preclinical animal model studies and toxicology
Key Technologies
- Proteolipid vehicle (PLV) nucleic acid delivery
- Fusion-associated small transmembrane (FAST) fusion proteins
- Plasmid DNA vectors (small/antibiotic-free selection vectors)
- Multiplexed payload encapsulation (DNA, mRNA, saRNA, siRNA, gene editing constructs, peptides)